DeepMed Research

Ferric carboxymaltose

Generic Name: Ferric carboxymaltose

Brand Names: Injectafer

Drug Type: Small Molecule

CAS Number: 9007-72-1

Unique Ingredient Identifier: 6897GXD6OE

Background: Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Indication: Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.

Associated Conditions: Iron Deficiency Anemia (IDA)

Clinical Trials

Patient Blood Management In CARdiac sUrgical patientS

Completed

Conditions: Anemia
Blood Loss Anemia
Iron Deficiency Anemia Treatment
Iron-deficiency
Erythropoiesis Abnormal
Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose
Drug: B vitamin
Drug: Folic acid

First Posted Date: 2021-02-08

Last Posted Date: 2022-07-06

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 479

Registration Number: NCT04744181

Locations: 🇮🇹
FPG Fondazione Policlinico Gemelli IRCCS, Roma, Italy

Preoperative i.v. Iron Substitution in Patients With Colon Cancer

Not Applicable

Recruiting

Conditions: Colon Cancer

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2020-12-04

Last Posted Date: 2024-02-29

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 514

Registration Number: NCT04653181

Locations: 🇫🇮
Jorvi Hospital, Espoo, HUS, Finland

Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?

Phase 4

Conditions: Iron Deficiency Anemia
B12 Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose
Drug: Hydroxycobalamin
Drug: Placebo

First Posted Date: 2020-11-13

Last Posted Date: 2021-01-29

Lead Sponsor: Christian Medical College, Vellore, India

Target Recruit Count: 100

Registration Number: NCT04627181

Locations: 🇮🇳
Christian Medical College, Vellore, Vellore, Tamil Nadu, India

Perioperative Management in Gynaecological Carcinoma Surgery

Phase 3

Withdrawn

Conditions: Gynaecological Carcinoma

Interventions: Drug: ferric carboxymaltose and tranexamic acid
Drug: ferric carboxymaltose
Drug: tranexamic acid

First Posted Date: 2020-11-12

Last Posted Date: 2025-04-14

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 126

Registration Number: NCT04625530

Locations: 🇨🇭
Department of Obstetrics and Gynaecology, University Hospital Basel, Basel, Switzerland

Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial

Phase 3

Conditions: Iron Deficiency Anemia
Inflammatory Bowel Diseases

Interventions: Drug: Sucrosomial iron
Drug: Ferric carboxymaltose
Drug: Ferric Gluconate

First Posted Date: 2020-10-14

Last Posted Date: 2020-10-19

Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Target Recruit Count: 300

Registration Number: NCT04587141

Locations: 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Iron Deficiency as an Ignored Cause of Infertility

Phase 4

Conditions: Iron Deficiency
Infertility

Interventions: Drug: Ferric Carboxymaltose Injection
Drug: NaCl infusion

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Dextra Fertility Clinic

Target Recruit Count: 62

Registration Number: NCT04510870

Locations: 🇫🇮
Dextra Fertility Clinic, Helsinki, Finland

Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation

Phase 4

Conditions: Blood Loss
Liver Transplantation

Interventions: Drug: Placebo
Drug: Iron Carboxymaltose

First Posted Date: 2020-07-17

Last Posted Date: 2020-07-28

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 60

Registration Number: NCT04475887

Locations: 🇦🇹
Medical University of Vienna, Department of Surgery, Vienna, Austria

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2020-02-17

Last Posted Date: 2022-03-21

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 7

Registration Number: NCT04269707

Locations: 🇺🇸
South Florida Research Phase I-IV, Miami Springs, Florida, United States
🇺🇸
Miami Clinical Research, Miami, Florida, United States

Intravenous Iron Injection in Cancer Patients With Anemia

Phase 3

Conditions: Cancer Anaemia

Interventions: Drug: Ferinject

First Posted Date: 2019-12-05

Last Posted Date: 2020-01-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 341

Registration Number: NCT04187716

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer

Phase 4

Not yet recruiting

Conditions: Anemia
Surgery
Gastric Cancer
Iron Deficiency Anemia
Surgery--Complications

Interventions: Drug: Placebos
Drug: Ferric carboxymaltose

First Posted Date: 2019-11-19

Last Posted Date: 2019-11-19

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 202

Registration Number: NCT04168346

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy